Biovica invites to market update on 18 August 15.00 – Bringing DiviTum®TKa to US patients

2022-08-15 15:00

Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa’s US market approval received on July 29 from the US Food and Drug Administration (FDA).

At the update on Thursday 18 August 15.00-16.00 CET, CEO Anders Rylander will give a short introduction. Joakim Arwidsson, VP RA/QA, about the 510(k) clearance, Henrik Winter, SVP Business Development, will describe the clinical application of the test and Warren Cresswell, President Americas, will describe the US Go-to-market plan.

DiviTum®TKa received 510(k) clearance on July 29, 2022, as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients.

Link to the event: Biovica International Market update FDA clearance 2022 (streamfabriken.com)

Some of our Collaborations

>3200

Numbers of patients in studies

24

Publications

10

Pharma Contracts